CHICAGO (EGMN) - AMG 386, a first-in-class recombinant peptide-Fc fusion protein, has been found to be active against advanced ovarian cancer, based on the results of a multisite phase II study."While VEGF may be the master regulator required to initiate angiogenesis, it must work with other factors including the angiopoietins to establish a network of capillaries and to establish blood flow," explained Dr. Beth Y. Karlan, lead author of a placebo-controlled phase II study that assessed two doses...